Document is current
Any future updates will be listed below
-
Authors
Rico-Fontalvo, Jorge https://orcid.org/0000-0002-2852-1241
Daza-Arnedo, Rodrigo https://orcid.org/0000-0002-6295-4972
Elbert, Alicia https://orcid.org/0000-0003-1993-9328
Correa-Rotter, Ricardo https://orcid.org/0000-0003-0100-8285
Dina-Batlle, Eliana https://orcid.org/0009-0007-5175-2041
Lorca-Herrera, Eduardo https://orcid.org/0000-0002-3670-075X
de Moraes, Thyago Proença https://orcid.org/0000-0002-2983-3968
Sánchez-Polo, Vicente https://orcid.org/0000-0003-3253-6363
Builes-Montaño, Carlos E. https://orcid.org/0000-0002-2418-6159
-
Funding
Funding for this research was provided by:
Sociedad Latinoamericana de Nefrología e Hipertensión
- License Information
-
More Information
Article History
Received: 12 December 2025
Accepted: 18 February 2026
First Online: 18 March 2026
Declarations
:
: The authors declare the following conflicts of interest. Rodrigo Daza-Arnedo has received speaker honoraria from Novo Nordisk, AstraZeneca, Bayer, and Boehringer Ingelheim. Alicia Elbert has been a member of the speaker boards of AstraZeneca, Boehringer Ingelheim, Novo Nordisk, Sanofi, Servier, Raffo, Baliarda, and Adium, and has served as an investigator in studies sponsored by Novo Nordisk, Boehringer Ingelheim, AstraZeneca, and Merck. Ricardo Correa-Rotter has served as a member of the Global Research Committee of FLOW and as national lead for the FLOW and TRIUMPH programs. Eliana Dina-Batlle declares no conflicts of interest. Eduardo Lorca-Herrera has participated in advisory boards for AstraZeneca, Boehringer Ingelheim, Axon Pharma, and Fresenius Medical Care; has received speaker honoraria from AstraZeneca, Boehringer Ingelheim, Novo Nordisk, and Axon Pharma; and has received travel or conference support from AstraZeneca, Boehringer Ingelheim, and Novo Nordisk. Thyago Proença de Moraes has received speaker or consulting fees from AstraZeneca, Bayer, Baxter/Vantive, Boehringer Ingelheim, CSL Vifor, Libbs, Lilly, Merck, Novo Nordisk, Servier, and Takeda. Vicente Sánchez-Poli has received speaker honoraria from Bayer, Boehringer Ingelheim, AstraZeneca, Novo Nordisk, Novartis, and Janssen. Jorge Rico-Fontalvo has received speaker honoraria from AstraZeneca, Boehringer Ingelheim, Novo Nordisk, Lilly, Sanofi, Eurofarma, Adium, GSK, MSD, Merck, and Bayer. He has participated in advisory boards for AstraZeneca, Boehringer Ingelheim, Adium, Lilly, Bayer, and Novo Nordisk. Carlos E. Builes-Montaño has received consulting and speaking fees from Sanofi, Novo Nordisk, Novartis, Recordati Rare Diseases, Janssen, Chiesi, Abbott, and Boehringer Ingelheim, and is a shareholder of Festina Lente. These disclosures are not necessarily related to the submitted work.
: Ethics approval was not required for this review because it is based exclusively on previously conducted, publicly available studies and does not contain any new studies with human participants or animals performed by any of the authors.
